Revive Therapeutics Ltd.
RVV
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -164.84% | -98.58% | -86.21% | -92.13% | 7.51% |
| Total Depreciation and Amortization | -100.00% | -100.00% | -100.00% | -100.00% | -75.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 300.19% | 286.02% | 281.63% | 278.84% | 123.99% |
| Change in Net Operating Assets | 23.46% | 250.57% | 876.01% | 409.56% | 217.38% |
| Cash from Operations | 84.91% | 91.38% | 86.94% | 77.16% | 71.62% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | 100.00% | 100.00% | -4,300.00% | 124.24% |
| Cash from Investing | -100.00% | 100.00% | 100.00% | -4,300.00% | 124.24% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 100.00% | 100.00% | 86.75% | 32.03% |
| Issuance of Common Stock | 76.93% | -92.92% | -92.92% | -- | -96.51% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -32.31% | -233.68% | -144.41% | -100.00% | 91.91% |
| Cash from Financing | 454.66% | -90.82% | -90.82% | -98.19% | -98.92% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 96.66% | 93.52% | 81.33% | 43.03% | 38.57% |